Abstract Noroviruses are small non-enveloped icosahedral viruses in the family Caliciviridae that cause a substantial fraction of acute gastroenteritis worldwide and drive both community disease and outbreaks in healthcare and other congregate settings[1–3]. Global burden estimates attribute approximately 685 million diarrheal cases annually to norovirus and approximately 212,489 deaths, with most mortality concentrated in developing countries[4]. These cases produce large economic losses, including estimates of approximately billion in annual societal costs and a dominant contribution of productivity losses (93%)[5]. Virologically, noroviruses have a positive-sense single-stranded RNA genome of ~7.5 kb organized into open reading frames encoding nonstructural replication proteins and the capsid proteins VP1 and VP2, with 180 copies of VP1 forming the icosahedral particle[6]. Host susceptibility and tropism are strongly shaped by interactions between the capsid protruding (P) domain and histo-blood group antigens (HBGAs), with genotype-specific binding mechanisms and additional enhancement by factors such as bile acids, whereas the definitive cellular receptor for human norovirus remains unknown[7, 8]. Clinically, infection typically causes nausea, vomiting, diarrhea, and abdominal pain and can be severe in young children, older adults, and immunocompromised patients, including prolonged shedding and chronic disease in transplant recipients[9, 10]. Prevention relies on outbreak infection-control measures (hand hygiene, limiting exposure, and environmental decontamination) and vaccine development, including oral vectored and mRNA-based candidates that induce HBGA-blocking antibodies and, in some settings, reduce viral shedding[11–13]. Treatment is primarily supportive, but investigational strategies include host-directed or direct-acting antivirals (e.g., nitazoxanide, ribavirin, nucleoside polymerase inhibitors) and entry inhibitors that block HBGA interactions, with organoid and enteroid culture systems increasingly enabling antiviral and disinfectant evaluation[9, 14–16].
1. Introduction
Norovirus is described as the most common cause of acute gastroenteritis globally and is associated with acute onset diarrhea and vomiting[17]. The viruses are non-enveloped and icosahedral members of the Caliciviridae family with particle diameters reported around ~38 nm[1]. In the United States, norovirus has been described as a leading cause of acute gastroenteritis and is associated with substantial annual illness and outbreak burden, including surveillance systems focused on outbreak reporting and strain typing[3, 18]. A major challenge in public health assessment is that many cases are not recognized or tested and individual cases are not routinely reportable to national systems, contributing to underestimation of sporadic burden and an emphasis on outbreak-based surveillance[19, 20].
2. Virology
Norovirus biology is defined by a small RNA genome, a VP1-driven capsid architecture with a highly variable outer surface, and strain-specific interactions with host glycans that affect susceptibility and likely shape population-level evolution[6, 7, 21].
2.1 Genome organization and structure
Norovirus genomes are positive-sense, single-stranded, polyadenylated RNA molecules of approximately 7.5 kb organized into three (or, in some descriptions, three or four) open reading frames[6]. ORF1 encodes a set of nonstructural proteins involved in replication, including NS1/2, NTPase (NS3), 3A-like (NS4), VPg (NS5), protease (NS6), and RNA-dependent RNA polymerase (NS7)[6]. ORF2 and ORF3 encode the major capsid protein VP1 and the minor capsid protein VP2, respectively[6]. Structural descriptions indicate that the virion is composed of 180 copies of VP1 (90 dimers) in a icosahedral arrangement[6]. VP1 is divided into shell and protruding domains, with the protruding region implicated as the principal site for antigenicity and interactions with cellular factors such as HBGAs[6].
2.2 Genogroups and genotypes
Noroviruses are genetically diverse, and VP1 sequence-based classification has been used to define genogroups and host-associated clusters in diverse mammals[22]. A more expansive classification scheme described in a recent synthesis indicates that noroviruses can be classified into at least ten genogroups (GI–GX) and more than forty genotypes[6]. Molecular typing has been updated to incorporate a dual-typing framework that uses both the RdRp-encoding region and the capsid region, yielding strain designations such as GI.1[P1][6]. Epidemiologic and surveillance-oriented summaries emphasize that among recognized genogroups, GI and GII cause the majority of human illness, with genotype GII.4 responsible for most outbreaks in recent years in some settings[23, 24].
2.3 Cellular receptors and tropism
A major mechanistic insight into norovirus susceptibility is that virus attachment to host cells in the gut is mediated by interactions with histo-blood group antigens (HBGAs), which can explain resistance or susceptibility phenotypes[7]. Multiple in vitro and structural approaches (including ELISA, surface plasmon resonance, and crystallography of P domains) have shown that binding properties vary by strain and depend on terminal residues and internal carbohydrate structures in the host glycans[7]. Genogroup-dependent binding patterns have been described, including observations that the majority of GI viruses interact with A and Lewis a antigens, while GII viruses show more diverse HBGA binding patterns, including binding to the B antigen in some strains[7]. Experimental work with recombinant Norwalk virus VLPs showed attachment to gastroduodenal epithelial cells and saliva components only from secretor donors and demonstrated that binding could be abolished by -fucosidase treatment and inhibited by competition with H type 1 and H type 3 trisaccharides, supporting a requirement for fucosylated ligands in secretor individuals[25].
Host genetics further modulate susceptibility through secretor status, with polymorphisms in FUT2 producing a nonfunctional enzyme in approximately 20–30% of people and resulting in “nonsecretor” status that prevents secretion of ABO antigens in body fluids[8]. Nonsecretors show significant resistance to infection with certain strains, including GI.1 and GII.4, though resistance is not absolute and infections can occur with some viruses[8]. Beyond glycans, an entry framework for non-enveloped viruses includes sequential attachment, receptor engagement, endocytosis, membrane penetration, and uncoating, and in calicivirus examples receptor binding can trigger VP2-mediated pore formation to permit genome delivery into the cytosol[8]. While CD300lf is identified as the murine norovirus receptor and is necessary and sufficient for murine infection, the receptor for human norovirus remains unknown, underscoring an important knowledge gap in human tropism[8].
Norovirus attachment can be modulated by additional factors, including bile acids and related molecules that function as attachment cofactors in some systems[8]. In enteroid-based replication systems, exogenous bile was required for replication of human GII.3 isolates and augmented replication of human GII.4 isolates, supporting a strain-dependent bile effect in human viruses[8].
2.4 Replication cycle
Direct descriptions of the full human norovirus replication cycle remain constrained by historical limitations in robust human culture systems, and the literature emphasizes that noroviruses were long considered noncultivatable in standard cell culture, making VLP-based systems central to mechanistic inference[26]. Within available mechanistic evidence, entry is described as a multistep process from attachment through endocytosis and genome delivery, with the minor capsid protein VP2 implicated as essential for infection and a candidate mediator of membrane penetration events in related caliciviruses[8].
2.5 Cultivation systems
Stem cell–derived human intestinal enteroids that support human norovirus replication have enabled experimental demonstration that human monoclonal antibodies with HBGA-blocking activity can neutralize human norovirus, strengthening the functional link between HBGA blockade and neutralization in a physiologically relevant model[6]. Reviews of organoid and enteroid systems emphasize that these in vitro platforms support replication of multiple genotypes and provide practical tools for vaccine and therapeutic development, including evaluation of virus neutralization and inactivation and measurement of disinfectant or sanitizer effectiveness[16].
2.6 Host immune response and antigenic variation
A central concept in norovirus immunology is that neutralization surrogates have been defined around blockade of HBGA carbohydrate interactions, particularly in contexts where traditional culture systems were historically unavailable, and HBGA-blocking antibodies have been treated as correlates of protection in vaccine design frameworks[6]. Experimental work on antibody blockade showed that convalescent human antisera efficiently blocked Norwalk VLP binding to H type 1 and related carbohydrates, whereas preinfection antisera did not, and vaccine-induced antisera in mice could block nearly 100% of H type 1 binding, providing a mechanistic bridge between antibody responses and inhibition of receptor engagement[27].
At the antigenic-structural level, the P2 subdomain is frequently described as the most diverse and protruding component of the capsid and is implicated in host interaction and immune recognition[1, 21]. Sequence-based analyses in GII.4 viruses identify hypervariability in the VP1 P2 domain and in VP2 regions involved in VP1 interaction, and show local minima of pairwise nucleotide similarity of 77–90% in these hypervariable regions despite overall VP1/VP2 nucleotide identity of ~95% across time-ordered strains[28]. Within-host evolution in chronic infection has been observed over months, with rapidly mutating VP1 and VP2 quasispecies, and codons under positive selection in both genes, supporting immune and/or functional selection pressures during persistence[28].
Several lines of evidence link antigenic drift and population immunity to epidemic dynamics in GII.4. For example, analyses comparing GII.4 2012 and GII.4 2015 indicate that substitutions in blockade antibody epitopes influence both antigenicity and ligand-binding properties, including complete loss of reactivity of a class of blockade antibodies due to epitope A changes and a 32% decrease in sera blockade potency at the population level[29]. Consistent with the “epochal evolution” paradigm, surveillance-associated reports describe ongoing emergence of novel GII.4 variants that can replace previously dominant strains and cause new pandemics, with amino acid changes in major epitopes located in the P2 domain during such emergence events[30].
Minor structural protein biology also influences capsid assembly and potentially genome packaging. VP2 associates with the interior surface of the VP1 shell domain, and VP1 residue Ile-52 within a conserved IDPWI motif was mapped as a critical determinant for VP1–VP2 association, because mutation at this site abrogated VP2 incorporation into VLPs while preserving VP1 dimerization and formation of ~35–40 nm VLPs[31]. Electrostatic analyses of the VP1 interior surface identified locally negative charge regions spanning the VP1 dimer near the Ile-52 pocket, and VP2 was described as highly basic (predicted ), supporting a proposed role for VP2 in counteracting electrostatic repulsion between RNA and capsid and stabilizing the encapsidated genome[31].
3. Epidemiology
Norovirus epidemiology is characterized by high global incidence, strong outbreak propensity in congregate settings, substantial under-ascertainment of sporadic cases, and rapid viral evolution—particularly in GII.4—that periodically reshapes strain dominance and disease activity[4, 32, 33].
3.1 Global burden
WHO estimates indicate that noroviruses annually cause approximately 685 million cases of diarrhea (95% CI 491 million–1.1 billion) and 212,489 deaths (95% CI 160,595–278,420), with approximately 85% of illnesses and approximately 99% of deaths occurring in developing countries[4]. Complementary syntheses emphasize that norovirus is associated with about 18% of diarrheal disease worldwide (95% CI 17–20) and is estimated to cause 212,000 deaths annually worldwide, with approximately 99% of deaths in middle- and high-mortality countries[33]. Economic analyses estimate a median billion annual societal cost (95% UI – billion), with billion in direct health system costs and billion in productivity losses and a high burden in children under 5 years of age[5].
3.2 Outbreak settings
Outbreak surveillance from the United States indicates that the majority of norovirus outbreaks occur in long-term care facilities and are commonly associated with person-to-person spread, reflecting the high transmissibility and setting vulnerability in institutional environments[3]. Historical outbreak analyses similarly found that GII.4 outbreaks occurred more frequently in long-term care facilities and cruise ships than other settings, whereas GI and other GII viruses were more often associated with restaurants and parties, indicating that setting distributions can vary across genogroups and lineages[34]. Public health surveillance emphasizes near real-time reporting and linkage of epidemiologic and genotyping information via integrated systems such as NoroSTAT, which connects outbreak reports with strain data to evaluate outbreak activity and strain-specific characteristics[18].
3.3 Transmission routes
Norovirus spreads through multiple transmission routes, with person-to-person and foodborne transmission described as the most important, and outbreak control relies on interventions such as hand hygiene, limiting exposure to infectious individuals, and thorough environmental decontamination[11]. Experimental studies of fomite spread show that contaminated fingers can sequentially transfer norovirus to up to seven clean surfaces, supporting a mechanistic basis for rapid environmental dissemination in high-touch contexts[35]. Surveillance-focused reports note that direct exposure to contaminated food accounts for less than 20% of cases in some estimates, implying a large contribution of other pathways such as direct contact and environmental spread[4].
3.4 Strain evolution and pandemic GII.4 variants
Public health laboratory surveillance demonstrates dominance of GII.4 viruses in the population and highlights that emergence of new GII.4 variants is associated with higher levels of infection and increased numbers of outbreaks, even when disease severity does not necessarily increase[32]. Molecular studies suggest that GII.4 is uniquely associated with pandemics among diverse genotypes, and that predominant GII.4 strains have higher mutation and evolutionary rates, including an average 1.7-fold higher rate of evolution within the capsid sequence, supporting rapid antigenic drift under immune selection[36]. Phylogenetic analyses of outbreak-derived VP1 sequences found that GII.4 viruses can be grouped into multiple subclusters with a proposed 5% amino-acid-variation cutoff for subcluster classification and an evolutionary pattern in which new subclusters gradually displace previous dominant strains, similar to patterns described for influenza virus[34].
Recombination and polymerase-capsid pairing are also important in contemporary molecular epidemiology. In the United States, a recombinant GII.4 Sydney harboring a novel GII.P16 polymerase emerged in 2015, replaced the GII.Pe-GII.4 Sydney strain, and remained predominant through the 2018–2019 season, with the GII.P16 polymerase also appearing in multiple capsid genotypes[37]. Whole-genome sequencing and phylogenetic analyses further suggest that GII.P16-GII.4 Sydney 2012 lineages have circulated since October 2014 or earlier in multiple regions and may have increased transmissibility driven by polymerase substitutions rather than unique capsid changes[38].
3.5 Seasonality
Norovirus activity often shows winter seasonality in multiple settings, and U.S.-focused summaries describe outbreaks as most common from November to April[24]. Population-based hospitalization modeling in Taiwan similarly observed winter seasonality with peaks in December–March, with epidemic years showing earlier peak timing (October–January) than nonepidemic years and peak seasons coinciding with emergence of new strains and resulting pandemics[39].
4. Clinical Disease
Norovirus infection most commonly presents as acute gastroenteritis but can lead to severe or prolonged disease in specific risk groups, and diagnostic interpretation is complicated by prolonged shedding and detection in asymptomatic individuals in the era of sensitive molecular testing[9, 40].
4.1 Acute gastroenteritis
Typical illness includes nausea, vomiting, diarrhea, and abdominal pain, and symptoms can be severe in children, older adults, and individuals with underlying diseases, potentially causing dehydration and rarely death[9]. The incubation period has been estimated as brief, approximately 1.2 days on average, supporting explosive outbreak kinetics and challenging case containment[41]. In one synthesis, symptoms were described as usually mild and disappearing within 48 hours after onset, though severity varies and quantitative severity data are limited in adults[41]. Diarrhea is reported as the predominant symptom in approximately 90% of cases and vomiting in approximately 75% of cases, supporting case definitions that include vomiting-only illness for norovirus surveillance and burden estimation[23, 41].
Virus shedding begins before onset of symptoms, can peak at approximately viral particles per gram of stool around day 4 after exposure, and may persist for many weeks in the general population or for months in immunocompromised individuals, supporting the need for continued infection control beyond symptom resolution in high-risk settings[41].
4.2 Diagnostic methods
Clinical reports emphasize that timely diagnosis often requires nucleic acid amplification testing, and clinicians are advised to obtain PCR testing for timely diagnosis and management in high-risk settings such as hematologic malignancy and transplant care[42]. In pediatric oncology, norovirus infection has been detected using multiplex PCR in symptomatic children, illustrating the practical role of syndromic molecular panels in diagnosing norovirus in complex patients[43]. At a population level, highly sensitive RT-qPCR has been noted to detect norovirus in stool of healthy individuals, complicating disease attribution and interpretation of positive tests[40].
4.3 Special populations
In immunocompromised children, norovirus infections can present with higher diarrhea frequency and longer viral shedding, and fever may be less prevalent compared with immunocompetent children with norovirus, potentially complicating clinical recognition based on systemic symptoms[44]. In adult renal allograft recipients, chronic infection defined by repeated positive stools over at least three months has been associated with prolonged shedding lasting 97–898 days and prolonged symptoms lasting 24–898 days, with hospitalizations for severe dehydration and allograft dysfunction reported in some patients[10]. In that transplant series, reduction of immunosuppression led to clinical improvement or recovery in all patients but viral shedding stopped in only a subset, illustrating a dissociation between symptom control and virologic clearance[10].
In hematologic malignancy and HSCT-associated cohorts, norovirus-associated diarrhea can be severe, with reports of substantial short-term mortality that is not directly attributable to norovirus itself and relatively infrequent use of norovirus-directed therapy, reinforcing the importance of supportive management and diagnostic vigilance[42].
4.4 Complications and extra-intestinal manifestations
Although norovirus is primarily an enteric pathogen, case-based synthesis has described norovirus-induced hepatitis with elevated ALT (146–458 IU/L) and AST (700–1150 IU/L) across 17 cases, with most patients under 18 years of age and most receiving supportive intravenous fluids[9]. In that compilation, all cases recovered fully with no fatality reported, suggesting that while transaminitis can occur, outcomes may be favorable with supportive care in reported cases[9]. Immunocompromised liver transplant recipients within these cases were reported to have prolonged recovery durations for symptoms and liver test abnormalities, indicating that immunosuppression can prolong systemic manifestations alongside enteric disease[9].
5. Prevention
Norovirus prevention requires both immediate outbreak control measures and longer-term strategies such as vaccination, but both approaches must address a pathogen characterized by environmental stability, high shedding, and broad genetic diversity[11, 45].
5.1 Vaccine development
Vaccine candidates increasingly target induction of serum and mucosal antibodies that block HBGA binding, consistent with HBGA blockade as a surrogate neutralization marker in vaccine design and human challenge models[6]. A trivalent mRNA-based vaccine candidate (mRNA-1403) encoding VP1 from three globally prevalent genotypes (GII.4, GI.3, and GII.3) has been evaluated in an ongoing Phase 1/2 randomized, placebo-controlled, dose-ranging study in adults 18–80 years, where it was well tolerated through 8 months and a single injection elicited robust serum HBGA-blocking antibodies and binding antibodies against vaccine-matched genotypes at 1 month post-dose across dose levels, informing Phase 3 dose selection[12].
Oral vaccine approaches have been assessed in controlled human infection models. In a double-blind, placebo-controlled oral challenge study of a nonreplicating adenovirus-vectored thermostable oral vaccine (VXA-G1.1-NN), 165 adults were randomized and 141 eligible subjects were challenged with genomic copies of NV GI.1; the vaccine showed 21% efficacy for prevention of norovirus gastroenteritis and 29% efficacy for prevention of infection and was associated with an 85% decrease in geometric mean viral shedding in stool, supporting a potential outbreak-mitigating effect through reduced shedding[13].
The table below summarizes key quantitative features of selected vaccine candidates described in the provided sources.
5.2 Challenges
Multiple sources emphasize that norovirus genetic and antigenic diversity complicates development of broadly effective vaccines and that cross-genotype protection is limited, motivating multivalent formulations and potential updating as strains evolve[45, 46]. A vaccine pipeline summary further notes that norovirus immunity is short-lived and does not generally provide strong cross-strain immunity, and that most studies have found immunity to the same strain lasts less than six months, implying that durable protection may require boosting or broadened coverage[47]. The same pipeline summary suggests that achieving high genotype coverage (e.g., 85%) might require inclusion of multiple genotypes in a multivalent vaccine concept, reflecting the breadth of circulating strains[47].
5.3 Non-pharmaceutical interventions
Norovirus outbreaks are difficult to prevent and control because of low infectious dose, high shedding titer, and environmental stability, and outbreak management relies on hand hygiene, limiting exposure to infectious individuals, and thorough environmental decontamination[11]. Evidence development for disinfection has been limited by historical inability to culture human norovirus, but newer experimental data using cultivable surrogates and environmental survivability studies are described as refining disinfection practices[11].
Mechanistic contamination studies show that transfer from contaminated fecal material via fingers and cloths to hand-contact surfaces can disseminate virus, and detergent-only cleaning that produces a visibly clean surface can fail to eliminate contamination, whereas combined hypochlorite/detergent formulations can reduce but not always eliminate detectable virus under conditions of fecal soiling[35]. Under heavy soiling, consistent hygiene required wiping the surface clean with detergent before disinfectant application, highlighting the importance of “cleaning before disinfection” protocols in norovirus outbreak control[35].
6. Treatment
No licensed antivirals are established for human norovirus, and clinical management is largely supportive, but investigational therapeutics span host-directed approaches, direct-acting polymerase and protease inhibitors, and entry inhibitors targeting HBGA interactions, with evaluation increasingly enabled by replicon systems and enteroid culture models[9, 14, 16, 48].
6.1 Supportive care
Clinical synthesis of norovirus-associated hepatitis and gastroenteritis emphasizes that management is mainly supportive, focusing on rehydration and correction of electrolyte abnormalities, consistent with the general approach to acute viral gastroenteritis[9]. Severe dehydration can require hospitalization in immunocompromised patients, including renal transplant recipients with chronic infection, reinforcing rehydration and supportive monitoring as core interventions in vulnerable populations[10].
6.2 Investigational antivirals
Nitazoxanide has been used in clinical case contexts for severe norovirus gastroenteritis in immunocompromised hosts, with one report describing initiation of oral nitazoxanide 500 mg twice daily and a rapid decline in bowel movement frequency within 24 hours and return to baseline within 4 days, though prolonged asymptomatic shedding persisted for over 30 days[49]. Mechanistic discussion in that report suggests nitazoxanide may modulate host antiviral pathways by potentiating PKR and phosphorylating eIF2α, thereby halting viral protein synthesis[49].
Replicon-based screening systems support quantitative evaluation of antiviral candidates. In NV replicon-bearing cells, IFN-α reduced NV protein and genome copies with an ED50 of approximately 2 units/mL at 72 hours, IFN-γ inhibited replication with an ED50 of approximately 40 units/mL, and ribavirin inhibited NV genome and protein with an ED50 of approximately 40 μM, with additive effects observed for IFN-α plus ribavirin and partial reversal by guanosine consistent with nucleotide depletion mechanisms[14]. In a persistent murine norovirus infection model in immunodeficient mice, the nucleoside polymerase inhibitor 2′-C-methylcytidine (2CMC) reduced stool shedding rapidly, rendered viral RNA undetectable during treatment, but was followed by rebound after cessation without evidence of drug-resistant mutations in sequenced samples, while favipiravir did not reduce viral shedding in that model[15].
Favipiravir has also been described in a clinical case of chronic norovirus infection in an immunocompromised patient, where treatment was associated with decreased diarrhea and viral load but complicated by rising liver enzymes prompting interruption and relapse, and viral sequencing showed selection of a distinct viral variant and increased minority mutations during treatment consistent with mutational pressure[50].
6.3 Immunotherapy
In hematologic malignancy and HSCT settings, norovirus-directed therapies have included nitazoxanide or intravenous immune globulin in a minority of patients, indicating that immunotherapy and antiviral trials remain limited and are often reserved for severe cases or persistent disease[42]. Chronic infection reports also note the importance of reducing immunosuppression when feasible, because intensity of immunosuppression correlates with diarrheal symptoms in transplant recipients and reduction can yield clinical improvement even when shedding persists[10].
6.4 Drug discovery enabled by enteroid systems
Therapeutic strategies targeting the virus–HBGA interaction are supported by structural biology defining HBGA-binding interfaces and by screening approaches that identify small molecules capable of blocking capsid–HBGA binding[51, 52]. Virtual screening and experimental validation using GII.4 VA387 structural models identified inhibitors from a 2.07 million compound library, yielding 20 compounds with >50% inhibition at concentrations below 40 μM and five compounds with IC50 <10 μM, with CC50 values reported in the ~170–267 μM range, supporting lead optimization for entry inhibition strategies[51].
Organoid and enteroid culture systems provide additional evaluation platforms. Reviews of human intestinal enteroid systems emphasize their utility for measuring virus neutralization and inactivation and for assessing disinfectant or sanitizer effectiveness, bridging discovery and translational evaluation for both therapeutics and infection control measures[16].
7. Future Directions
Future progress will depend on integrating molecular surveillance with mechanistic virology to anticipate strain emergence and on developing broadly protective vaccines and therapeutics that account for rapid evolution, recombination, and limited cross-genotype immunity[32, 45, 53]. Surveillance frameworks emphasize that linking epidemiology with virology is key because outbreak counts and laboratory reports indicate infection levels but do not directly specify circulating strains without integrated genotyping systems, motivating continued expansion and modernization of systems such as NoroSTAT and CaliciNet linkages[32, 54]. Molecular evolutionary analyses indicate that pandemic GII.4 viruses can diversify and spread for years prior to recognized pandemic emergence and that changes in host population immunity enable pandemic spread of antigenically preadapted variants, implying that improved sampling of unsampled reservoirs could improve forecasting and vaccine strain selection[53].
From an immunologic perspective, evidence that immunity to the same strain can be short-lived and that cross-strain immunity is limited implies that next-generation vaccines may need to be multivalent and potentially updated as new variants emerge, similar in concept to approaches used for other rapidly evolving viruses[46, 47]. On the therapeutic front, the absence of licensed antivirals coupled with proof-of-concept results in replicon systems, animal models, and clinical case reports underscores the need for rigorous clinical trials and for leveraging human enteroid models to bridge the gap between in vitro antiviral activity and clinical efficacy in diverse patient populations[15, 16, 48].
8. Conclusion
Norovirus remains a leading cause of acute gastroenteritis globally, with approximately 685 million cases of diarrhea and over 200,000 deaths annually in global estimates and substantial societal cost, emphasizing its ongoing public health importance[4, 5, 33]. The virus’s biology—an RNA genome encoding replication and structural proteins, a VP1-based capsid with a highly variable P2 surface, and genotype-dependent HBGA engagement modulated by host genetics—connects mechanistically to observed patterns of strain dominance, outbreak propensity, and immune escape[6, 7, 21, 30]. Clinically, most infections are self-limited but high-risk groups can experience severe and chronic disease with prolonged shedding, necessitating targeted diagnostic strategies and infection control alongside supportive care[10, 41, 42]. Vaccine candidates and investigational antivirals demonstrate meaningful progress, particularly those inducing HBGA-blocking responses or reducing shedding in challenge models, but diversity and short-lived immunity remain central obstacles that reinforce the need for integrated surveillance, multivalent vaccine design, and therapeutics tested in modern human-relevant culture systems[12, 13, 16, 47].
